Cargando…

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging

[Image: see text] Phosphodiesterase 5 (PDE5) is a clinically relevant biomarker and therapeutic target for many human pathologies, yet a noninvasive agent for the assessment of PDE5 expression has yet to be realized. Such agents would improve our understanding of the nitric oxide (NO)/cyclic guanosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailey, Justin J., Wuest, Melinda, Bojovic, Tamara, Kronemann, Travis, Wängler, Carmen, Wängler, Björn, Wuest, Frank, Schirrmacher, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388084/ https://www.ncbi.nlm.nih.gov/pubmed/34471776 http://dx.doi.org/10.1021/acsomega.1c03315

Ejemplares similares

Bimodal Imaging Probes for Combined PET and OI: Recent Developments and Future Directions for Hybrid Agent Development
por: Seibold, Uwe, et al.
Publicado: (2014)

t-Bu(2)SiF-Derivatized D(2)-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging
por: Iovkova-Berends, Ljuba, et al.
Publicado: (2011)

(89)Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges
por: Fischer, Gabriel, et al.
Publicado: (2013)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
por: Shafiee, Arman, et al.
Publicado: (2023)

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) (18)F-Radiopharmaceuticals
por: Gower-Fry, Lexi, et al.
Publicado: (2021)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y(1))R‐Specific Imaging Agents
por: Krieger, Korbinian, et al.
Publicado: (2020)

iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with (68)Ga and (64)Cu: Unexpected Findings
por: Litau, Shanna, et al.
Publicado: (2018)

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
por: Judmann, Benedikt, et al.
Publicado: (2023)

Synthesis of a Bifunctional Cross‐Bridged Chelating Agent, Peptide Conjugation, and Comparison of (68)Ga Labeling and Complex Stability Characteristics with Established Chelators
por: Damerow, Helen, et al.
Publicado: (2022)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
por: Mietens, Andrea, et al.
Publicado: (2011)

Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
por: Judmann, Benedikt, et al.
Publicado: (2020)

Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors
por: Judmann, Benedikt, et al.
Publicado: (2022)

Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain
por: Liu, Jianrong, et al.
Publicado: (2016)

Side-by-Side Comparison of Five Chelators for (89)Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability
por: Damerow, Helen, et al.
Publicado: (2021)

Synthesis, Radiolabeling, and In Vitro and In Vivo Characterization of Heterobivalent Peptidic Agents for Bispecific EGFR and Integrin α(v)β(3) Targeting
por: Braun, Diana, et al.
Publicado: (2023)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y(1))- and GRP-Receptors—An Improvement for Breast Cancer Imaging?
por: Vall-Sagarra, Alicia, et al.
Publicado: (2018)

Hybrid Multimodal Imaging Synthons for Chemoselective and Efficient Biomolecule Modification with Chelator and Near-Infrared Fluorescent Cyanine Dye
por: Hübner, Ralph, et al.
Publicado: (2020)

Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α(v)β(3) and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?
por: Cheng, Xia, et al.
Publicado: (2021)

(18)F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals
por: Bernard-Gauthier, Vadim, et al.
Publicado: (2014)

Comparison of scandium-44 g with other PET radionuclides in pre-clinical PET phantom imaging
por: Ferguson, Simon, et al.
Publicado: (2019)

Dosimetry of [(18)F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans
por: Thiel, Alexander, et al.
Publicado: (2023)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

Synthesis of a 2-nitroimidazole derivative N-(4-[(18)F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([(18) F]FBNA) as PET radiotracer for imaging tumor hypoxia
por: Nario, Arian Pérez, et al.
Publicado: (2022)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease
por: Cesarini, Valeriana, et al.
Publicado: (2020)

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
por: Rybalkina, Irina G, et al.
Publicado: (2011)

α(v)β(3)-Specific Gold Nanoparticles for Fluorescence Imaging of Tumor Angiogenesis
por: Pretze, Marc, et al.
Publicado: (2021)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease
por: Tomita, Natsumi, et al.
Publicado: (2020)

Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression
por: Catalano, Stefania, et al.
Publicado: (2019)

Toward in vivo proof of binding of (18)F-labeled inhibitor [(18)F]TRACK to peripheral tropomyosin receptor kinases
por: Wuest, Melinda, et al.
Publicado: (2022)

The effect of phosphodiesterase-5 inhibitor, tadalafil, on in vitro potassium chloride-induced contractions of isolated human ureteral tissue
por: Sakthivel, M. S., et al.
Publicado: (2018)

A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis
por: Sugimoto, Mikio, et al.
Publicado: (2019)

Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line
por: Bimonte, Viviana M., et al.
Publicado: (2021)

Radiometal-Containing Aryl Diazonium Salts for Chemoselective Bioconjugation of Tyrosine Residues
por: Leier, Samantha, et al.
Publicado: (2019)

Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection
por: Foulke-Abel, Jennifer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_funob523nk6f39bhlab1g9qce1